Covaxin has been approved for emergency use in children over the age of 2

NEW DELHI: Bharat Biotech’s Covaxin is said to have gotten approval from the Subject Expert Committee (SEC) on COVID-19 for emergency usage in children above the age of two in India.

According to reports, the SEC has filed recommendations to the Drugs Controller General of India (DCGI) for the vaccine’s approval for use on children.

Covaxin will become the only vaccination authorised for use on children and the only such vaccine for toddlers if it is approved. The three-dose DNA jab developed by Zydus Cadilla was approved for use on adults and children over the age of 12 in August.

In September, the Hyderabad-based business completed Phase 2 and Phase 3 studies of Covaxin on children under the age of 18.

The Serum Institute’s Novavax vaccine is a third potential vaccination for children, and the DCGI approved studies for youngsters aged seven to eleven years old last month.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s